Himension Capital Singapore PTE. LTD. Makes New $260,000 Investment in Twist Bioscience Corporation $TWST

Himension Capital Singapore PTE. LTD. bought a new stake in Twist Bioscience Corporation (NASDAQ:TWST) in the 1st quarter, Holdings Channel reports. The institutional investor bought 5,481 shares of the company’s stock, valued at approximately $260,000.

Other hedge funds have also recently made changes to their positions in the company. Strs Ohio bought a new stake in shares of Twist Bioscience during the first quarter worth about $33,000. PNC Financial Services Group Inc. grew its holdings in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after acquiring an additional 453 shares during the last quarter. Quarry LP acquired a new position in Twist Bioscience in the 3rd quarter valued at approximately $28,000. Strategic Advocates LLC increased its position in Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after acquiring an additional 906 shares during the period. Finally, Fifth Third Bancorp bought a new position in shares of Twist Bioscience during the first quarter valued at $54,000.

Twist Bioscience Stock Down 1.7%

Shares of NASDAQ TWST opened at $94.21 on Thursday. The firm has a market cap of $5.87 billion, a PE ratio of -70.83 and a beta of 2.11. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $105.47. The company’s fifty day simple moving average is $79.96 and its 200 day simple moving average is $59.47. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The company had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. During the same quarter in the previous year, the business posted ($0.66) earnings per share. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 18,880 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $95.00, for a total value of $1,793,600.00. Following the completion of the sale, the chief executive officer directly owned 824,039 shares of the company’s stock, valued at $78,283,705. The trade was a 2.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 14,205 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75. Following the transaction, the insider directly owned 105,141 shares in the company, valued at approximately $9,436,404.75. This trade represents a 11.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 50,711 shares of company stock worth $4,230,246 over the last 90 days. 3.08% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TWST. Leerink Partners set a $110.00 price objective on shares of Twist Bioscience in a research note on Thursday, July 16th. Guggenheim raised their target price on Twist Bioscience from $60.00 to $107.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. TD Cowen lifted their target price on Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a report on Monday, June 15th. Barclays raised their price objective on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Finally, Canaccord Genuity Group upped their price objective on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $90.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.